Pharmacokinetics of Non-Psychotropic Phytocannabinoids

被引：0
作者：
Lacerda, Mariana [1 ]
Carona, Andreia [1 ,2 ]
Castanheira, Sara [1 ]
Falcao, Amilcar [1 ,2 ]
Bicker, Joana [1 ,2 ]
Fortuna, Ana [1 ,2 ]
机构：
[1] Univ Coimbra, Fac Pharm, Lab Pharmacol & Pharmaceut Sci, P-3004531 Coimbra, Portugal
[2] Univ Coimbra, Coimbra Inst Biomed Imaging & Translat Res, CIBIT, P-3004531 Coimbra, Portugal
来源：
PHARMACEUTICS | 2025年 / 17卷 / 02期
关键词：
cannabidiol; cannabichromene; cannabigerol; cannabidiolic acid; cannabichromenic acid; cannabigerolic acid; pharmacokinetics; CANNABIS; BLOOD; EXPOSURE;
D O I：
10.3390/pharmaceutics17020236
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Cannabinoids are widely recognized for their potential therapeutic effects, making them significant and valuable candidates for medical research and applications across various fields. This review aims to analyze the pharmacokinetics of Cannabidiol (CBD), Cannabigerol (CBG), and Cannabichromene (CBC), along with their corresponding acidic forms, Cannabidiolic acid (CBDA), Cannabigerolic acid (CBGA), and Cannabichromenic acid (CBCA). Among these cannabinoids, CBD is the most extensively studied. Nevertheless, research involving all the mentioned cannabinoids has shown that their pharmacokinetic parameters are highly variable, depending significantly on factors such as dose, formulation, route of administration, and diet. Furthermore, challenges such as brain penetration and first-pass metabolism have been highlighted. In conclusion, this review demonstrates significant progress in understanding the pharmacokinetics of non-psychotropic cannabinoids. However, it also underscores the need for further research, particularly on CBG, CBC, and their respective acidic forms, with the most significant gap being in clinical investigations. Expanding these studies is essential to facilitate their optimized use in medical treatments.
引用
收藏
页数：21
相关论文
共 67 条
  • [1] Radwan M.M., Chandra S., Gul S., Elsohly M.A., Cannabinoids, Phenolics, Terpenes and Alkaloids of Cannabis, Molecules, 26, (2021)
  • [2] Gulck T., Moller B.L., Phytocannabinoids: Origins and Biosynthesis, Trends Plant Sci, 25, pp. 985-1004, (2020)
  • [3] Walsh K.B., McKinney A.E., Holmes A.E., Minor Cannabinoids: Biosynthesis, Molecular Pharmacology and Potential Therapeutic Uses, Front. Pharmacol, 12, (2021)
  • [4] Lipinski C.A., Dominy B.W., Feeney P.J., Drug Delivery Reviews Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings, Adv. Drug Deliv. Rev, 23, pp. 3-25, (1997)
  • [5] Pajouhesh H., Lenz G.R., Medicinal Chemical Properties of Successful Central Nervous System Drugs, NeuroRX, 2, pp. 541-553, (2005)
  • [6] Reddy T.S., Zomer R., Mantri N., Nanoformulations as a Strategy to Overcome the Delivery Limitations of Cannabinoids, Phytother. Res, 37, pp. 1526-1538, (2023)
  • [7] Deiana S., Watanabe A., Yamasaki Y., Amada N., Arthur M., Fleming S., Woodcock H., Dorward P., Pigliacampo B., Close S., Et al., Plasma and Brain Pharmacokinetic Profile of Cannabidiol (CBD), Cannabidivarine (CBDV), Δ9-Tetrahydrocannabivarin (THCV) and Cannabigerol (CBG) in Rats and Mice Following Oral and Intraperitoneal Administration and CBD Action on Obsessive-Compulsive Behaviour, Psychopharmacology, 219, pp. 859-873, (2012)
  • [8] Di Marzo V., Piscitelli F., The Endocannabinoid System and Its Modulation by Phytocannabinoids, Neurotherapeutics, 12, pp. 692-698, (2015)
  • [9] Di Salvo A., Conti M.B., della Rocca G., Pharmacokinetics, Efficacy, and Safety of Cannabidiol in Dogs: An Update of Current Knowledge, Front. Vet. Sci, 10, (2023)
  • [10] Matei D., Trofin D., Iordan D.A., Onu I., Condurache I., Ionite C., Buculei I., The Endocannabinoid System and Physical Exercise, Int. J. Mol. Sci, 24, (2023)
1234567